BullishAgent BullishAgent Filings Economic Earnings Ratings IPOs Insiders Institutional ETFs Funds Screener
Sign in Register

CLLS

Cellectis S.A. NASDAQ Listed Mar 24, 2015
Healthcare ·Biotechnology ·FR · cellectis.com
$3.82
Mkt Cap $382.9M
52w Low $1.33 60.0% of range 52w High $5.48
50d MA $3.69 200d MA $3.69
P/E (TTM) -5.8x
EV/EBITDA -26.6x
P/B 5.2x
Debt/Equity 1.6x
ROE
P/FCF -11.4x
RSI (14)
ATR (14)
Beta 2.71
50d MA $3.69
200d MA $3.69
Avg Volume 44.2K
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
SIC Code
2836
CIK (SEC)
Phone
33 1 81 69 16 00
8, rue de la Croix Jarry · Paris 75013 · FR
Data updated apr 26, 2026 10:10am · Source: massive.com